Pharma major, Zydus Cadila today informed that the company has received the final approval from the US drug regulator to market Telmisartan tablets in the US market.
On Friday, the company stated that the US Food and Drug Administration (USFDA) has granted final approval to market Telmisartan Tablets of 20mg, 40mg and 80mg.
The estimated sales in 2014 for Telmisartan tablets, which fall in the anti-hypertensive segment is $233.3 million, as per IMS.
The group now has 96 approvals and has so far filed 249 ANDAs since the commencement of the filing process in FY 2003-04, a company statement stated.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.